[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2093735T3 - Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica. - Google Patents

Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.

Info

Publication number
ES2093735T3
ES2093735T3 ES92107865T ES92107865T ES2093735T3 ES 2093735 T3 ES2093735 T3 ES 2093735T3 ES 92107865 T ES92107865 T ES 92107865T ES 92107865 T ES92107865 T ES 92107865T ES 2093735 T3 ES2093735 T3 ES 2093735T3
Authority
ES
Spain
Prior art keywords
sleep disorders
therapy
melatonin derivatives
anesthetic medication
disorders therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92107865T
Other languages
English (en)
Inventor
Gabriele Biella
Franco Fraschini
Bojidar Stankov
Strambi Luigi Ferini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
I F L O ISTITUTO FARMACOLOGICO
Original Assignee
I F L O ISTITUTO FARMACOLOGICO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I F L O ISTITUTO FARMACOLOGICO filed Critical I F L O ISTITUTO FARMACOLOGICO
Application granted granted Critical
Publication of ES2093735T3 publication Critical patent/ES2093735T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTE INVENTO MUESTRA NUEVAS COMPOSICIONES FARMACEUTICAS ACTIVAS EN LA TERAPIA DE DESARREGLOS DEL SUEÑO QUE COMPRENDEN N ERIVADOS, PREFERENTEMENTE 2 TRIPTAMINA (2 METOXI TRIPTAMINA (2 NA DOSIS COMPRENDIDA ENTRE 10 Y 100 MG, PREFERENTEMENTE COMPRENDIDOS RESPECTIVAMENTE ENTRE 20 Y 80 MG, ENTRE 10 Y 20 MG Y ENTRE 10 Y 40 MG, SOLOS O EN ASOCIACION CON UN DERIVADO BENZODIAZEPINICO EN UNA DOSIS COMPRENDIDA ENTRE 0,06 Y 25 MG.
ES92107865T 1991-05-13 1992-05-11 Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica. Expired - Lifetime ES2093735T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI911299A IT1251544B (it) 1991-05-13 1991-05-13 Composizioni farmaceutiche attive nella terapia dei disturbi del sonno comprendenti melatonina o un suo derivato in associazione con un derivato benzodiazepinico

Publications (1)

Publication Number Publication Date
ES2093735T3 true ES2093735T3 (es) 1997-01-01

Family

ID=11359886

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92107865T Expired - Lifetime ES2093735T3 (es) 1991-05-13 1992-05-11 Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
ES95118386T Expired - Lifetime ES2139132T3 (es) 1991-05-13 1992-05-11 Composiciones farmaceuticas activas en la terapia de desordenes del sueño.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES95118386T Expired - Lifetime ES2139132T3 (es) 1991-05-13 1992-05-11 Composiciones farmaceuticas activas en la terapia de desordenes del sueño.

Country Status (9)

Country Link
US (1) US5430029A (es)
EP (2) EP0513702B1 (es)
JP (1) JPH05155769A (es)
AT (2) ATE142877T1 (es)
DE (2) DE69230046T2 (es)
DK (2) DK0713701T3 (es)
ES (2) ES2093735T3 (es)
GR (2) GR3022060T3 (es)
IT (1) IT1251544B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2082959T3 (es) * 1990-09-28 1996-04-01 I F L O S A S Di Giorgio E Ald Procedimiento para desarrollar la sintesis de una droga contraceptiva y de control del ciclo menstrual que tiene propiedades anticinetosicas, oncostaticas y terapeuticas para el tratamiento de los tumores de mama y melanomas.
IT1255199B (it) * 1992-07-01 1995-10-20 Franco Fraschini Farmaco sintetizzato analogo della melatonina particolarmente efficacenelle patologie che interferiscono con i ritmi circadiani
IT1254995B (it) * 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
IT1262912B (it) * 1992-12-30 1996-07-22 Impiego della melatonina nella terapia della sclerosi sistemica, della sarcoidosi ed altro
AU726758B2 (en) * 1993-11-18 2000-11-23 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US6180657B1 (en) * 1993-11-18 2001-01-30 Eli Lilly And Company Melatonin derivatives for use in treating desynchronization disorders
US5654325A (en) * 1993-11-18 1997-08-05 Eli Lilly And Company Melatonin derivatives for use in treating sleep disorders
JPH09511514A (ja) * 1994-04-07 1997-11-18 セ・エ・エム・ア・エフ 新規メラトニン作用性アゴニストのスピロ［インドールピロリジン］誘導体とその製造方法および医薬品としての用途
US6469044B1 (en) 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
BR9607169A (pt) * 1995-02-01 1997-11-11 Neurim Pharma 1991 Uso de meletonina e formulação farmacêutica para uso no tratamento de um viciado em drogas múltiplas
ATE247967T1 (de) * 1998-06-09 2003-09-15 Takeda Chemical Industries Ltd Pharmazeutische kombination mit einem trizyclischen komponent und mindestens einem aus zolpidem, zopiclone und brotizolam, zur behandlung von schlafstörungen
FR2787447B1 (fr) * 1998-12-18 2001-03-23 Centre Nat Rech Scient Nouveaux derives de melatonine et medicament comprenant de tels derives
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CN1346278A (zh) * 1999-02-05 2002-04-24 曼彻斯特维多利亚大学 麻醉的调节
US6638966B2 (en) 2000-09-19 2003-10-28 University Of Iowa Research Foundation Use of melatonin analogues for induction of general anesthesia
US6552064B2 (en) * 2000-09-19 2003-04-22 University Of Iowa Research Foundation Use of melatonin for induction of general anesthesia
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) * 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
PT1691811E (pt) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
US20050215521A1 (en) * 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
AU2004308962A1 (en) * 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
WO2005079851A2 (en) * 2004-02-18 2005-09-01 Sepracor, Inc. Dopamine-agonist combination therapy with sedatives for improving sleep quality
US8053462B2 (en) 2004-03-08 2011-11-08 Masanori Somei Indole derivative and application thereof
JP3964417B2 (ja) 2004-09-27 2007-08-22 国立大学法人金沢大学 インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤
AR056076A1 (es) * 2005-09-20 2007-09-19 Takeda Pharmaceutical Agente profilactico o terapeutico para el desorden de sueno
WO2007137244A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Melatonin agonist treatment
CA2861108C (en) 2012-01-26 2020-09-08 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN105142630A (zh) 2012-12-18 2015-12-09 万达制药公司 昼夜节律紊乱的治疗
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11690849B2 (en) 2019-04-12 2023-07-04 LA PharmaTech Inc. Method of treating dementia
US11938139B2 (en) 2019-04-12 2024-03-26 LA PharmaTech Inc. Pharmaceutical compositions and methods for anxiety, depression and other psychiatric disorders
US11744833B2 (en) 2019-04-12 2023-09-05 LA PharmaTech Inc. Pharmaceutical compositions and methods for treatment of insomnia
JP7088153B2 (ja) * 2019-09-19 2022-06-21 カシオ計算機株式会社 Ｃａｐ（周期性脳波活動）検出装置、ｃａｐ（周期性脳波活動）検出方法及びプログラム
WO2023158424A1 (en) * 2022-02-16 2023-08-24 La Pharma Tech Inc. Novel pharmaceutical compositions and methods for treatment of insomnia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3466215D1 (en) * 1983-05-18 1987-10-22 Univ Monash The use of melatonin for the manufacture of a medicament
EP0375726A4 (en) * 1987-08-17 1991-01-30 Whitby Research Incorporated Melatonin analogues

Also Published As

Publication number Publication date
IT1251544B (it) 1995-05-17
DE69230046D1 (de) 1999-10-28
GR3032207T3 (en) 2000-04-27
DE69230046T2 (de) 2000-05-31
EP0713701B1 (en) 1999-09-22
EP0513702A3 (en) 1992-11-25
ATE184792T1 (de) 1999-10-15
ES2139132T3 (es) 2000-02-01
ATE142877T1 (de) 1996-10-15
DK0713701T3 (da) 2000-04-03
DE69213814D1 (de) 1996-10-24
ITMI911299A0 (it) 1991-05-13
US5430029A (en) 1995-07-04
DE69213814T2 (de) 1997-04-03
EP0513702A2 (en) 1992-11-19
EP0713701A1 (en) 1996-05-29
ITMI911299A1 (it) 1992-11-13
DK0513702T3 (da) 1996-12-30
JPH05155769A (ja) 1993-06-22
GR3022060T3 (en) 1997-03-31
EP0513702B1 (en) 1996-09-18

Similar Documents

Publication Publication Date Title
ES2093735T3 (es) Derivados de melatonina para uso en la terapia de trastornos del sueño y en medicacion preanestesica.
AR004179A1 (es) Sales de (endo,sin)-(-)-3-(3-hidroxi-1-oxo-2-fenilpropoxi)-8-metil-8-(1- metiletil)-8-azoniabiciclo[3.2.1] octano y preparaciones medicamentosasinhalativas que las contienen.
MX9203444A (es) Medicamentos.
GT200000041A (es) Uso de inhibidores de cyp2d6 en terapias de combinacion.
ES2082288T3 (es) Composiciones terapeuticas para administracion intranasal de ketorolaco.
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
YU46095A (sh) Postupak pripreme leka za inhalacionu primenu
AR009231A1 (es) Formulaciones en aerosol de formoterol.
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
CO5410187A1 (es) Formulacion oral de dosis unica de espinosad
CO5200840A1 (es) Combinacion de sustancias activas con clonidina
CO4230093A1 (es) Derivados del indol y sus usos medicos
IT1263840B (it) Formulazioni orali di ubidecarenone in forma di capsule
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
ES2090712T3 (es) Medicamento agudo que contiene ibuprofeno y su uso.
IT1244636B (it) Uso dell'acetil l-carnitina nel trattamento terapeutico del coma e composizioni farmaceutiche utili in tale trattamento.
ES2054718T3 (es) El uso de gepirona para la preparacion de una composicion farmaceutica para el tratamiento de la depresion atipica.
ES2171459T3 (es) Polvo para administracion nasal de farmaco peptidico o proteinaceo.
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
DK0615443T3 (da) Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 513702

Country of ref document: ES